Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sulzer Hip Recall Settlement Exceeds $1 Bil., Doubles Patient Damages

This article was originally published in The Gray Sheet

Executive Summary

Sulzer Medica is in negotiations with CMS to broker a global settlement for Medicare patients affected by the firm's hip and knee implant recall

You may also be interested in...



Sulzer Changes Name To Centerpulse, Will Approve Class Settlement May 22

Sulzer Medica will attempt to reduce the financial impact of 132 opt-out cases from its class action settlement, reiterating that the firm may file for Chapter 11 bankruptcy to avoid settling those claims

Sulzer Changes Name To Centerpulse, Will Approve Class Settlement May 22

Sulzer Medica will attempt to reduce the financial impact of 132 opt-out cases from its class action settlement, reiterating that the firm may file for Chapter 11 bankruptcy to avoid settling those claims

Sulzer Medica

Injunction against individual lawsuits related to the firm's Inter-Op hip shell and Natural Knee II tibial baseplate component recall is extended from Feb. 22 to March 8 "to allow sufficient time to complete the wording" of Sulzer's proposed class-action settlement agreement, Sulzer says Feb. 22 (1"The Gray Sheet" Feb. 11, 2002, p. 14)...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016101

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel